Dmitrij Hristodorov is General Partner at Forbion. His current portfolio covers various stages, treatment modalities and disease areas.
To date, he serves as a board member for RyCarma, Complement, Seamless, AAVantgarde, Kynexis, Beacon, and Mosanna. He previously served as a board observer of VectorY Therapeutics, as a board observer and R&D committee member of Gyroscope Therapeutics that was acquired for up to $1.5Bn by Novartis in December 2021, as a board director of Rampart Bio, and as a board director of Oxular that was acquired by Regeneron in 2025.
Before joining Forbion, he held roles in R&D Ophthalmology and Business Development at Bayer Pharma.
In 2013 he received his PhD degree summa cum laude from the University of Aachen (RWTH) for the work he performed at Fraunhofer Institute in immunology.
After having worked in academia and Pharma, Forbion provides me with the opportunity to understand and merge the last two pillars of the life science ecosystem: VC and biotech. An integrative approach to all these perspectives in one team is what makes Forbion a successful group.
Portfolio
Companies worked on by Dmitrij Hristodorov
